Selective orexin 2 receptor agonist TAK-925 to treat narcolepsy: results of a randomized, double-blind, placebo-controlled, multiple-ascending-dose, phase 1 study in patients with narcolepsy type 2

被引：0
|
作者：
Tanaka, S. -I. [1 ]
Evans, R. [2 ]
Alexander, R. [2 ]
Imazaki, M. [1 ]
Touno, S. [1 ]
Shimizu, K. [1 ]
Wu, J. [2 ]
Faessel, H. [2 ]
Ratti, E. [2 ]
Hartman, D. [1 ]
机构：
[1] Takeda Pharmaceut Co Ltd, Takeda Dev Ctr Japan, Osaka, Japan
[2] Takeda Pharmaceut Int Co, Neurosci Therapeut Area Unit, Cambridge, MA USA
来源：
JOURNAL OF SLEEP RESEARCH | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P206
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [21] Safety, Tolerability, and Pharmacokinetics of Therapeutic and Supratherapeutic Doses of Tramadol Hydrochloride in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Multiple-Ascending-Dose Study
    DeLemos, Byron
    Richards, Henry M.
    Vandenbossche, Joris
    Ariyawansa, Jay
    Natarajan, Jaya
    Alexander, Binu
    Ramakrishna, Tage
    Murtaugh, Thomas
    Stahlberg, Hans-Juergen
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (06): : 592 - 603
  • [22] Oral JZP-110 phase 2b study for the treatment of excessive sleepiness in adults with narcolepsy: Results of a randomized, double-blind, placebo-controlled trial
    Black, J.
    Swick, T.
    Feldman, N.
    Doekel, R., Jr.
    Khayrallah, M.
    Bream, G.
    Ruoff, C.
    SLEEP MEDICINE, 2015, 16 : S36 - S36
  • [23] EFFICACY AND SAFETY OF AXS-12 IN THE TREATMENT OF NARCOLEPSY: RESULTS FROM A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER TRIAL
    O'Gorman, C.
    Jones, A.
    Thorpy, M. J.
    Tabuteau, H.
    SLEEP, 2020, 43 : A281 - A281
  • [24] Double-blind, placebo-controlled phase 1 single ascending dose study of sage-718
    Murck, H.
    Paskavitz, J.
    Hoffmann, E.
    Li, S.
    Silber, C.
    Quirk, M.
    Varoglu, M.
    Webster, I.
    Sankoh, A.
    Doherty, J.
    Kanes, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S128 - S128
  • [25] Repaglinide in type 2 diabetes: A randomized, double-blind, placebo-controlled, dose-response study
    Schwartz, SL
    Goldberg, RB
    Strange, P
    DIABETES, 1998, 47 : A98 - A98
  • [26] A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple, Intravenous, Ascending-Dose Study of Sirukumab in Patients with Cutaneous or Systemic Lupus Erythematosus.
    Szepietowski, Jacek C.
    Nilganuwong, Surasak
    Wozniacka, Anna
    Kuhn, Annegret
    Nyberg, Filippa
    Szechinski, Jacek
    van Vollenhoven, Ronald F.
    Bengtsson, Anders
    Reich, Adam
    de Vries, Dick
    van Hartingsveldt, Bart
    Zhou, Bei
    Hsu, Benjamin
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S496 - S497
  • [27] SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL GLP-1/FGF21 DUAL AGONIST HEC88473 IN TYPE 2 DIABETES PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1b/2a MULTIPLE-ASCENDING-DOSE STUDY
    Xiang, Lin
    Ding, Hua Yan
    Yan, Jiangyu
    Luo, Lin
    Zhang, Hong
    Xie, Can
    Peng, Yu Yu
    Chen, Hong
    Li, Qian Qian
    Li, Xiao Ping
    Zhuang, Yu Lei
    Guo, Linfeng
    HEPATOLOGY, 2024, 79 (02) : E67 - E68
  • [28] A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST (ACT-541468) TO TREAT INSOMNIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE-REFERENCE PHASE 2 STUDY
    Dauvilliers, Yves
    Zammit, Gary
    Fietze, Ingo
    Mayleben, David
    Kinter, Dalma Seboek
    Pain, Scott
    Hedner, Jan
    SLEEP, 2019, 42
  • [29] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Wallace, Daniel J.
    Furie, Richard
    Tanaka, Yoshiya
    Kalunian, Kenneth C.
    Mosca, Marta
    Petri, Michelle
    Dorner, Thomas
    Cardiel, Mario H.
    Bruce, Ian N.
    Gomez, Elisa
    DeLozier, Amy M.
    Janes, Jonathan
    Linnik, Matthew D.
    de Bono, Stephanie
    Silk, Maria E.
    Hoffman, Robert W.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [30] Efficacy and Safety of JZP-258 in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults with Narcolepsy with Cataplexy
    Foldvary-Schaefer, Nancy
    Bogan, Richard K.
    Thorpy, Michael J.
    Dauvilliers, Yves
    Villegas, Rafael Del Rio
    Partinen, Markku
    Skowronski, Roman
    Tang, Lihua
    Skobieranda, Franck
    Sonka, Karel
    ANNALS OF NEUROLOGY, 2020, 88 : S250 - S251
12345